Daniel J. Lippis - 16 Jan 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
16 Jan 2025
Net transactions value
-$11,744
Form type
4
Filing time
16 Jan 2025, 17:07:44 UTC
Previous filing
16 Dec 2024
Next filing
13 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $22,638 +500 +2.2% $45.28 23,689 16 Jan 2025 Direct F1
transaction EW Common Stock Sale $34,382 -500 -2.1% $68.76 23,189 16 Jan 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -500 -25% $0.000000 1,530 16 Jan 2025 Common Stock 500 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $68.42 to $69.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.